Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I. (1/13)

Pictorial review of mucopolysaccharidosis with emphasis on MRI features of brain and spine. (2/13)

Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. (3/13)

Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy. (4/13)

Oral enzyme therapy for celiac sprue. (5/13)

Celiac disease: advances in treatment via gluten modification. (6/13)

Evaluation of a gene-directed enzyme-product therapy (GDEPT) in human pancreatic tumor cells and their use as in vivo models for pancreatic cancer. (7/13)

Modeling of pharmacokinetics of cocaine in human reveals the feasibility for development of enzyme therapies for drugs of abuse. (8/13)

• 1
• 2